Human Dermal Fibroblasts-Type 1 Diabetes (HDF-T1D)

Overview

Human Dermal Fibroblasts-Type 1 Diabetes (HDF-T1D) is a cell model used for research applications where physiologically relevant identity and donor background support interpretation of experimental readouts. Human Fibroblasts derived from Skin (Dermal -Type 1 Diabetes) within the Integumentary system.

Human Dermal Fibroblasts (HDF) are the most prevalent cell in human dermis, and one of the most important architects of cutaneous would healing [1] . The fibroblast is a malleable cell, capable of altering its function and physiology or even transforming into a new cell type, based on its location within the body. The dermal fibroblast also has the unique title of being the first human somatic cell to be induced into a pluripotent stem cell line [2,3] . iXCells Biotechnologies provides high quality Human Dermal Fibroblasts (HDF) from normal donors including neonatal foreskin ( Cat# 10HU-013 ) and adult skin ( Cat# 10HU-014 ), or from adult skin of Type 1 Diabetes patients. These cells are derived from the dermis of normal human neonatal foreskin or adult skin and cryopreserved at the end of primary culture. HDF are negative for HIV-1, HBV, HCV, mycoplasma, bacteria, yeast, and fungi. They can further expand in Fibroblast Growth Medium ( Cat# MD-0011 ) for no more than 3 passages under the condition suggested by iXCells Biologies. Further expansion may decrease the proliferation rate and purity. Figure 1. (A) Human Neonatal Dermal Fibroblasts (10HU-013). (B) Human Adult Dermal Fibroblasts (10HU-014).

Key elements and design rationale

• Cell identity: Fibroblasts (Primary Cells)
• Source context: Skin; Dermal -Type 1 Diabetes; Integumentary
• Donor background: Age: Neonatal, Adult
• Biosafety level: BSL-2 (follow your institution’s biosafety program and local regulations)

Product-specific elements (such as tissue source, donor background, and cell classification) help frame how results should be interpreted across assays and experimental conditions.

Biological background

Fibroblasts are key stromal cells that produce and remodel extracellular matrix, coordinate wound repair, and shape tissue microenvironments through paracrine signaling.

Across primary and specialty cell models, experimental outcomes can be influenced by donor heterogeneity, passage history, confluence, and media composition. For interpretation, it is common to validate key markers or functional phenotypes in the user’s assay context and to document culture variables consistently.

Research relevance and current trends

• Increasing use of primary and specialty cells to improve translational relevance for target biology and phenotypic screening.
• Adoption of 3D culture formats and co-culture systems to better capture tissue microenvironments and cell–cell interactions.
• Integration of functional readouts with single-cell and multi-omics profiling to connect phenotype with molecular state.

Common research applications

• Profile identity markers by flow cytometry or immunostaining in cultured cells
• Quantify functional responses to defined stimuli relevant to the model system
• Compare baseline phenotype across donors/conditions using gene expression profiling
• Model wound-healing–relevant signaling and extracellular matrix interactions
• Screen compounds or genetic perturbations for phenotype modulation using viability or imaging endpoints

Interpretation typically focuses on how a perturbation (e.g., cytokine exposure, metabolic stress, genetic manipulation, or compound treatment) shifts marker profiles or functional readouts relative to an appropriate control matched for donor and culture variables.

Notes for experimental interpretation

• Donor-to-donor heterogeneity can influence baseline phenotype and treatment response; include biological replicates when feasible.
• Passage number, confluence, and media composition can shift gene expression and functional readouts; track and report these variables consistently.
• Contamination control (including routine mycoplasma monitoring) supports reproducibility in downstream assays.
• Use appropriate negative/positive controls for the readout (e.g., unstimulated controls, pathway agonists/antagonists) to contextualize observed changes.

SKU:BHC18500070

Customization & Add-ons: Can't find the cell line you need—or require a custom cell-based solution for your project? We can help you source the best match or support custom cell line services for diverse research needs, including cell line sourcing and selection (species, tissue, and disease model matching), stable cell line engineering (overexpression, knockdown, or knockout via CRISPR/Cas9, shRNA, or sgRNA), reporter gene integration (GFP, RFP, luciferase, and other fluorescent or bioluminescent constructs), genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles), inducible expression systems (Tet-On/Off and other regulatable constructs), drug resistance marker selection (puromycin, G418, hygromycin, and others), custom growth and media optimisation for specific assay requirements, scale-up production for high-throughput screening campaigns, and authentication and QC services (STR profiling, mycoplasma testing, viability assessment). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.